Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471642 | 0.91 | MAOB (0.55) | MAOBMAOAHRH3GRM5HSD17B1 | |
| SCHEMBL315565 | 0.91 | MAOB (0.55) | MAOBMAOAGRM5HSD17B1 | |
| SCHEMBL1513396 | 0.89 | MAOB (0.46) | MAOBMAOAHRH3DRD2HTR1D | |
| SCHEMBL2089994 | 0.85 | DRD2 (0.42) | MAOBMAOADRD2HTR1DDRD3 | |
| SCHEMBL3988527 | 0.83 | MAOB (0.64) | MAOBMAOAHSD17B1 | |
| SCHEMBL1513290 | 0.80 | MAOA (0.53) | MAOBMAOAHRH3DRD2HTR1D | |
| SCHEMBL16499744 | 0.80 | HSD11B1 (0.40) | MAOBMAOADRD2HTR1DDRD3 | |
| SCHEMBL1239457 | 0.80 | MAOB (0.60) | MAOBMAOACASP1CASP7HSD17B10 | |
| SCHEMBL5685785 | 0.80 | MAOB (0.49) | MAOBMAOACASP1CASP7HSD17B10 | |
| SCHEMBL1417460 | 0.79 | PARP10 (0.51) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | UNIVERSITAT DE VALENCIA-ESTUDI GENERAL (ES) | 2025-07-08 | — | — | US | disclosed |
| US-20220160745-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | UNIVERSITAT DE VALÈNCIA-ESTUDI GENERAL (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3930728-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | Universitat de Valencia - Estudi General (ES) | 2022-01-05 | — | — | EP | disclosed |
| CN-113473993-A | Methods and compositions for treating motor neuron diseases | 巴伦西亚大学 | 2021-10-01 | — | — | CN | disclosed |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2009-10-29 | — | — | US | disclosed |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2009-10-29 | — | — | US | disclosed |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | UNIVERSITAT DES SAARLANDES (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| EP-1877049-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | Universidade Federal de Minas Gerais (BR) | 2008-01-16 | — | — | EP | disclosed |
| EP-1768654-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2006102728-A2 | INCLUSION COMPOUNDS OF DIOCLEIN, FLORANOL OR ANALOGS WITH CYCLODEXTRIN AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006008316-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | MAOB 247/4885MAOA 470/4885CASP1 196/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | MAOB 247/4885MAOA 470/4885CASP1 196/4885 |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | HSD11B1, HSD11B2, CYP11B1 | MAOB 456/4885MAOA 1449/4885CASP1 3176/4885 |
| US-20220160745-A1 | METHODS AND COMPOSITIONS FOR TREATING MOTOR NEURON DISEASES | SMN1; SMN2, NNMT, PDE4A | MAOB 243/4885MAOA 635/4885CASP1 467/4885 |
| US-20090270495-A1 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof | PDE5A, PDE12, PDE2A | MAOB 330/4885MAOA 193/4885CASP1 922/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | MAOB 25/4885MAOA 46/4885CASP1 474/4885 |
| US-12350283-B2 | Methods and compositions for treating motor neuron diseases | SMN1; SMN2, NNMT, PDE4A | MAOB 243/4885MAOA 635/4885CASP1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.